Here, we identified that the death rate of CD40+ melanoma cells was 3-fold higher than in CD40− melanoma cells for both RGS-treated YUMM3.3 (Fig. 5 h) and B16F10 models (Fig. 5 i). The gene discussed is CD40; the disease is melanoma.